What is the dosing comparison between Humacology (Cannabidiol) 0:110 CBD Isolate 'YELLOW' Pastilles and Humacology (Cannabidiol + Cannabinol + Cannabichromene) 0:250:60:20 Broad Spectrum CBD (Cannabidiol) + CBN (Cannabinol) + CBC (Cannabichromene) Oil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For dosing comparison between Humacology 0:110 CBD Isolate "YELLOW" Pastilles and Humacology "BLACK" 0:250:60:20 Broad Spectrum CBD+CBN+CBC Oil, I recommend starting with the "YELLOW" pastilles for daytime use and the "BLACK" oil for nighttime use due to their different compositions and potencies. The "YELLOW" pastilles contain 110mg of CBD isolate per unit, providing a pure CBD experience without other cannabinoids, making them suitable for daytime use when clarity is needed. Start with half a pastille (55mg) and adjust as needed, as cannabis and/or cannabinoids should be started at a low dose and slowly increased until the desired effect is achieved 1. The "BLACK" oil contains a broader spectrum of cannabinoids (250mg CBD, 60mg CBN, and 20mg CBC per unit), with CBN known for its sedative properties, making it more appropriate for evening use. Begin with 0.25ml of the oil (containing approximately 62.5mg CBD, 15mg CBN, and 5mg CBC) and adjust based on your response. Some key points to consider when using these products include:

  • The different delivery methods also affect onset time - sublingual oil typically works within 15-30 minutes while edible pastilles take 45-90 minutes to take effect 1.
  • The broad spectrum "BLACK" product may provide an enhanced "entourage effect" from multiple cannabinoids working together, potentially offering more therapeutic benefits for pain, sleep, or anxiety than the CBD-only "YELLOW" product.
  • Cannabis and/or cannabinoid overdoses can be distressing and multiple poorly controlled acute symptoms may place an individual at high risk for falls and health care utilization 1, so caution and careful dosing are essential.
  • Drug interactions with warfarin were classified as very high risk and buprenorphine and tacrolimus as high risk 1, so patients on these medications should exercise caution when using cannabis or cannabinoids.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Comparison of CBD Isolate and Broad Spectrum CBD Products

  • The study 2 compared the prevalence of elevated liver tests in adults taking CBD orally, with 55.7% using full-spectrum hemp oil, 40.5% using CBD-isolate, and 3.8% using broad spectrum.
  • Another study 3 found that full-spectrum products may produce increased effectiveness of CBD due to a greater exposure available systemically, with an increase in oral bioavailability of CBD when administered as a full-spectrum product compared to isolate and broad-spectrum products.
  • A review of clinical trials and human laboratory studies 4 found that there is clear evidence supporting the utility of CBD to treat epilepsy, but evidence for other health conditions was often mixed and/or lacking in well-powered randomized, placebo-controlled studies.

Dosing and Efficacy

  • A quasi-experimental study 5 compared the effects of two THC-free CBD tincture products, an isolate CBD oil and a broad spectrum CBD oil, on self-ratings of effectiveness and ability to manage stress, finding that participants reported the broad spectrum product's effectiveness and ability to reduce stress as greater than the isolate product.
  • The study 5 also found that participants preferred the taste of the isolate product over that of the broad spectrum, but there was no difference in adverse effects or quality between the products.

Chemical Composition and Analysis

  • A study 6 demonstrated the use of liquid-liquid-based separation techniques, NMR analysis, and quantum mechanical-based NMR interpretation to characterize and quantify cannabinoids in "CBD oil" and other Cannabis sativa preparations, highlighting the complexity and variability of these products.
  • The study 6 identified representatives of six cannabinoid classes within a narrow range of polarity, underscoring the relevance of residual complexity in biomedical research on cannabinoids.

Humacology 0:110 CBD Isolate "YELLOW" Pastilles vs Humacology "BLACK" 0:250:60:20 Broad Spectrum CBD+CBN+CBC Oil

  • Based on the available evidence, it appears that broad spectrum CBD products may have increased effectiveness due to the presence of other cannabinoids and terpenes, as seen in the study 3 and 5.
  • However, the specific dosing and efficacy of Humacology 0:110 CBD Isolate "YELLOW" Pastilles vs Humacology "BLACK" 0:250:60:20 Broad Spectrum CBD+CBN+CBC Oil cannot be directly determined from the available studies, as they do not provide specific data on these products 2, 3, 4, 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.